Skip to main content

Combination of high throughput technologies advances antibody development

The antibody development infrastructure U-READ at the Dept. of Immunotechnology, headed by Prof. Mats Ohlin, in collaboration with the Department of Laboratory Medicine, and BioInvent International AB, have demonstrated the utility of a combination of next generation sequencing and bioinformatics as a screening tool to isolate novel cell-bindning antibodies not readily identified by conventional immunochemical screening. This opens up for novel opportunities in the development of antibodies to novel disease-associated targets.

– Published 10 May 2023

The study is presented in Cell Reports Methods.